
Onconic swings to profit in Q1 as Jaqbo sales hit 10 bil. won in 6 months
Onconic Therapeutics reported a sharp turnaround in its first-quarter earnings, driven by strong sales of its gastroesophageal reflux drug Jaqbo (zastaprazan), one of Korea’s newest domestically developed treatments. The company, a subsidiary of Jeil …